McKesson is expected to report Q1 2026 revenue of $101.61 billion and EPS of $11.56, with the current stock price of $807.85 trading significantly below the average analyst target of $986.73.
Investors are primarily focused on the growth trajectory of the U.S. Pharmaceutical segment and the margin impact from the continued distribution of high-demand GLP-1 weight loss medications.
The company has maintained strong momentum with seven consecutive quarterly earnings beats, largely driven by specialty product distribution and expansion within its oncology platform.
Recent analyst sentiment remains cautiously optimistic, though some experts watch for potential regulatory headwinds and the long-term sustainability of the GLP-1 distribution tailwind as market supply stabilizes.